Channavix Therapeutics, LLC is developing a portfolio of novel, non-addictive, non-opioid analgesics that provide multi-week pain relief with local administration. Our programs are being developed for acute and chronic pain conditions for both human and veterinary markets.

Mr. Monroe has over 30 years of management experience. He has a background in mergers & acquisitions, technology transactions, and corporate finance. Mr. Monroe has been operationally involved in biotech since 2008, holding positions of CFO and EVP at Serometrix, and in 2014 became CEO of Serometrix. Mr. Monroe also founded Peregrine Capital Partners, LLC, a boutique investment banking firm focused on middle market companies. Mr. Monroe holds a B.S. from the School of Management at State University of New York at Buffalo, and an M.B.A. from the S.C. Johnson Graduate School of Management at Cornell University.

Dr. Barta has over 30 years of medicinal chemistry experience which includes Pharmacia, where his research group was involved in anti-inflammatory drug discovery, leading to the approval of the cyclooxygenase II inhibitor Celebrex, Serenex where he worked on oncology targets including heat shock protein 90 inhibitors that entered Phase I clinical trials before the company was acquired by Pfizer, and Serometrix where he helped discover novel allosteric PCSK9 inhibitors. Dr. Barta has a B.S. in Chemistry from the Massachusetts Institute of Technology. His Ph.D. in Organic Chemistry is from the University of Rochester, where he studied with Professor R.K. Boeckman. He also completed an NIH postdoctoral fellowship at Northwestern University in Organic Chemistry with Professor A.G.M. Barrett.